Trials / Active Not Recruiting
Active Not RecruitingNCT06553027
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Complications
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- Sponsor
- Cerevance · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CVN424 75 mg | Participants will receive 75 mg CVN424 tablet once daily. |
| DRUG | CVN424 150 mg | Participants will receive 150 mg CVN424 tablet once daily. |
| DRUG | Placebo | Participants will receive matching placebo tablet once daily. |
Timeline
- Start date
- 2024-09-20
- Primary completion
- 2026-08-01
- Completion
- 2026-08-01
- First posted
- 2024-08-14
- Last updated
- 2026-04-17
Locations
94 sites across 9 countries: United States, Australia, Czechia, France, Italy, Poland, Puerto Rico, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06553027. Inclusion in this directory is not an endorsement.